US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

CNS/Neurology Market Research Reports & Industry Analysis

RSS Feeds

CNS/Neurology Industry Research & Market Reports

3  4  5  6    8    10  11  12  
Update: Attention Deficit Hyperactivity Disorder Pipeline Highlights – 2014
5/1/2014 | published by: Fore Pharma
... Hyperactivity Disorder market. It covers emerging therapies for Attention Deficit Hyperactivity Disorder in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking ...  |  read more...
USD 590
Update: Bipolar Disorder Pipeline Highlights – 2014
5/1/2014 | published by: Fore Pharma
... therapies for Bipolar Disorder in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development ...  |  read more...
USD 590
Update: Neuroblastoma Pipeline Highlights – 2014
5/1/2014 | published by: Fore Pharma
... in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing ...  |  read more...
USD 590
Update: Opioid Addiction Pipeline Highlights – 2014
5/1/2014 | published by: Fore Pharma
... therapies for Opioid Addiction in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development ...  |  read more...
USD 590
MediPoint: Neurovascular Interventions - South America Analysis and Market Forecasts
4/30/2014 | published by: GlobalData
... neurovascular interventions and development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. The neurovascular interventions market consists of four device segments including embolization, revascularization, mechanicalthrombectomy and access/support devices. The neurovascular interventions ...  |  read more...
USD 4,450
Market Highlights: France Depression – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, depression drugs market share, depression drugs sales estimates, depression drugs sales forecast, and depression late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: Japan Depression – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, depression drugs market share, depression drugs sales estimates, depression drugs sales forecast, and depression late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: Europe Depression – 2014
5/1/2014 | published by: Fore Pharma
... research includes Europe (Germany, France, Italy, Spain, and UK) depression market size estimates for 2013, market share forecast for six years to 2019, depression drugs market share, depression drugs sales estimates, depression drugs sales forecast, ...  |  read more...
USD 2,800
Market Highlights: Spain Migraine – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, migraine drugs market share, migraine drugs sales estimates, migraine drugs sales forecast, and migraine late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: Japan Migraine – 2014
5/1/2014 | published by: Fore Pharma
... market size estimates for 2013, market share forecast for six years to 2019, migraine drugs market share, migraine drugs sales estimates, migraine drugs sales forecast, and migraine late stage pipeline products.This research helps executives track ...  |  read more...
USD 990
Market Highlights: Europe Migraine – 2014
5/1/2014 | published by: Fore Pharma
... research includes Europe (Germany, France, Italy, Spain, and UK) migraine market size estimates for 2013, market share forecast for six years to 2019, migraine drugs market share, migraine drugs sales estimates, migraine drugs sales forecast, ...  |  read more...
USD 2,800
Market Highlights: Spain Bipolar Disorder – 2014
5/1/2014 | published by: Fore Pharma
... research includes Spain bipolar disorder market size estimates for 2013, market share forecast for six years to 2019, bipolar disorder drugs market share, bipolar disorder drugs sales estimates, bipolar disorder drugs sales forecast, and bipolar ...  |  read more...
USD 990
Market Highlights: US Bipolar Disorder – 2014
5/1/2014 | published by: Fore Pharma
... US. The research includes the US bipolar disorder market size estimates for 2013, market share forecast for six years to 2019, bipolar disorder drugs market share, bipolar disorder drugs sales estimates, bipolar disorder drugs sales ...  |  read more...
USD 990
MediPoint: Neurovascular Interventions - APAC Analysis and Market Forecasts
4/30/2014 | published by: GlobalData
... interventions and development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. The neurovascular interventions market consists of four device segments including embolization, revascularization, mechanicalthrombectomy and access/support devices. The APAC neurovascular interventions ...  |  read more...
USD 4,450
Brain Metastasis Global Clinical Trials Review, H1, 2014
2/26/2014 | published by: GlobalData
... information and data relating to the clinical trials on Brain Metastasis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook ...  |  read more...
USD 2,500
Brain Cancer Global Clinical Trials Review, H1, 2014
2/26/2014 | published by: GlobalData
... information and data relating to the clinical trials on Brain Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook ...  |  read more...
USD 2,500
Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022
2/28/2014 | published by: GlobalData
... fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the ...  |  read more...
USD 3,495
Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022
2/28/2014 | published by: GlobalData
... fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the ...  |  read more...
USD 3,495
Geodon (Schizophrenia) - Forecast and Market Analysis to 2022
2/28/2014 | published by: GlobalData
... fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the ...  |  read more...
USD 3,495
Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022
2/28/2014 | published by: GlobalData
... fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the ...  |  read more...
USD 3,495
Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022
2/28/2014 | published by: GlobalData
... fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the ...  |  read more...
USD 3,495
EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022
2/28/2014 | published by: GlobalData
... fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the ...  |  read more...
USD 3,495
PharmaPoint: Schizophrenia - Japan Drug Forecast and Market Analysis to 2022
2/28/2014 | published by: GlobalData
... accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. ...  |  read more...
USD 4,995
PharmaPoint: Schizophrenia - US Drug Forecast and Market Analysis to 2022
2/28/2014 | published by: GlobalData
... accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. ...  |  read more...
USD 4,995
PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022
2/28/2014 | published by: GlobalData
... accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. ...  |  read more...
USD 6,995
3  4  5  6    8    10  11  12